A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

13.3K views

DOI:

10.3791/51741

July 20th, 2014

In This Article

Summary

There is a discernible need for improved information on molecular drivers of Barrett’s Esophagus. Immunofluorescent staining is a useful technique for understanding the effects of cell signaling on cell morphology. We present a simple, effective protocol for the use of immunofluorescent staining to assess therapeutic treatment in Barrett’s Esophagus cells.

Abstract

Esophageal adenocarcinoma (EAC) has an overall survival rate of less than 17% and incidence of EAC has risen dramatically over the past two decades. One of the primary risk factors of EAC is Barrett’s esophagus (BE), a metaplastic change of the normal squamous esophagus in response to chronic heartburn. Despite the well-established connection between EAC and BE, interrogation of the molecular events, particularly altered signaling pathways involving progression of BE to EAC, are poorly understood. Much of this is due to the lack of suitable in vitro models available to study these diseases. Recently, immortalized BE cell lines have become commercially available allowing for in vitro studies of BE. Here, we present a method for immunofluorescent staining of immortalized BE cell lines, allowing in vitro characterization of cell signaling and structure after exposure to therapeutic compounds. Application of these techniques will help develop insight into the mechanisms involved in BE to EAC progression and provide potential avenues for treatment and prevention of EAC.

Introduction

Barrett’s esophagus (BE) is a metaplastic change in the normal squamous epithelium of the esophagus and a consequence of chronic exposure to the gastric contents resulting from gastroesophageal reflux disease (GERD)1. BE is thought to be a protective mechanism in response to GERD, however the presence of BE imparts an increased risk of esophageal adenocarcinoma (EAC), a disease which carries a significantly poor survival1. Current estimates suggest that up to 5.6% of the American population have BE, however as BE is often asymptomatic, it is thought that the majority of BE remains undiagnosed2. As incidence rates of both GERD and....

Access restricted. Please log in or start a trial to view this content.

Protocol

1. Cell Line Maintenance

  1. Immortalized Human BE high-grade dysplastic (CP-B, CP-C, CP-D) and metaplastic (CP-A) cell lines by stable transfection of the human telomerase reverse transcriptase (TERT) protein11.
  2. Maintain BE cell lines in keratinocyte media supplemented with bovine pituitary extract (BPE), epidermal growth factor (EGF), 5% fetal bovine serum (FBS), nonessential amino acids (NEAA), penicillin-streptomycin-neomycin (PSN), and standard tissue culture conditions (37 °C, 5% CO2, 98% humidity).

2. BE Cell Plating

  1. Preparation of 12-well plate/coverslips. Place 18 mm c....

Access restricted. Please log in or start a trial to view this content.

Results

An example of the results obtained from application of the described procedures is illustrated in Figures 1A-D. Coverslips with CP-D and CP-C BE cells were treated for 24 hr with 1 μM of the Src family inhibitor, SKI-606, or vehicle (DMSO) and stained using the above procedures for the Adherens Junction and Wnt signaling protein, β-catenin. Visualization of β-catenin was achieved by labeling with an anti-rabbit IgG coupled to a green fluorophore, while labeling of the cell nucleus was accomplished by lab.......

Access restricted. Please log in or start a trial to view this content.

Discussion

We have outlined a method for application of IF of BE cells towards elucidating the physiological effects of targeted therapies upon these cells. While we have described the use of these procedures towards BE cells, we have found that these methods are also applicable to a variety of different cell types13,17,18. Further, these procedures can be altered in several ways to optimize staining for specific targets.

We find one parameter that has a direct effect upon proper IF is the cho.......

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors declare that they have no competing financial interests.

Acknowledgements

This work was supported by grants from the St, Joseph’s Foundation (AJF, LJI) and American Lung Association, RG-224607-N (LJI).

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
CP-A (Metaplastic Cell Line)ATCCCRL-4027
CP-B (High-grade Dysplastic Cell Line)ATCCCRL-4028
CP-C (High-grade Dysplastic Cell Line)ATCCCRL-4029
CP-D (High-grade Dysplastic Cell Line)ATCCCRL-4030
Keratinocyte-SFM (1x), LiquidLife Technologies17005-042
0.25% Trypsin-EDTA (1x), Phenol Red Life Technologies25200056
Fetal Bovine Serum, Qualified, HILife Technologies10438026
PSN antibiotic mixtureLife Technologies15640
PBS - Phosphate-Buffered SalineLife Technologies10010049
Pro-long Gold Antifade Reagent with DAPI Life TechnologiesP36931
Circular Glass Coverslip 18 mmFisher Scientific15-183-86
β-catenin Primary Antibody (Rabbit)Cell Signaling9562S
Alexa Fluor 488 (Goat Anti-Rabbit)Life TechnologiesA11008
10 cm TC treated PS dish, sterileUSA ScientificCC7682-3394
12-well TC treated PS plate, sterileUSA Scientific5666-5180
DMSOSigma-Aldrich276855
ParaformaldehydeSigma-AldrichP6148
Ammonium chlorideSigma-AldrichA9434
SaponinSigma-Aldrich47036
Bovine Serum Albumin - Fraction VSigma-Aldrich85040C
SKI-606 (Bosutinib)Selleck ChemicalsS1014
Square Bioassay Dish Thermo Scientific240835
Parafilm VWR82024-546
Disposable Pasteur Pipettes, Flint GlassVWR14672-380
Nexcelom Mini Cell CounterNexcelom
Cellometer Counting ChambersNexcelomCHT4-SD100-014
Zeiss Apotome microscope Zeiss

References

  1. Reid, B. J., Li, X., Galipeau, P. C., Vaughan, T. L. Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat. Rev. Cancer. 10, 87-101 (2010).
  2. Hayeck, T. J., Kong, C. Y., Spechler, S. J., Gazelle, G. S., Hur, C.

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Tags

Barretts Esophagus CellsImmunofluorescent StainingProtein LocalizationFluorescence MicroscopyCell Structure AnalysisDrug Treatment EffectsPrimary Antibody IncubationSecondary Antibody ConjugationFixative PreservationCover Slip Preparation